文献速递治疗药物监测与药物基因组学抗菌药物管理

基于唾液的治疗药物监测用于利奈唑胺的临床研究

Clinical research for saliva-based therapeutic drug monitoring of linezolid.
PubMed 文献 · Br J Clin Pharmacol · 2024-10-10

该研究纳入18例接受口服或静脉利奈唑胺治疗的患者,同时测定血浆和唾液药物浓度。唾液/血浆浓度比均值为1.018,两者呈强相关(R=.833,P<.001),静脉给药者相关性更强(R=.885,P<.001),提示唾液监测可能替代血浆监测。

要点

  • 唾液与血浆利奈唑胺浓度高度相关,支持唾液用于治疗药物监测。
  • 静脉给药患者唾液/血浆相关性更强,可能更适合唾液监测。
  • 夜间谷浓度唾液/血浆比更接近1.0,提示采样时机可能影响准确性。

核心结论

  • 利奈唑胺血浆与唾液浓度相似,唾液监测在临床中具有潜在适用性。
  • 唾液监测尤其适合接受静脉给药的利奈唑胺患者。

研究设计与样本

  • 研究纳入2022年4月至2024年7月期间在北海道大学医院和北海道脊髓损伤中心住院并接受口服或静脉利奈唑胺治疗的患者。
  • 共18例患者入组,同时采集血浆和唾液样本测定利奈唑胺浓度并分析相关性。

主要发现

  • 唾液/血浆浓度比平均值为1.018。
  • 唾液与血浆利奈唑胺浓度呈强相关(R=.833,P<.001)。
  • 静脉给药患者中唾液与血浆浓度相关性更强(R=.885,P<.001)。
  • 早晨和夜间谷浓度的唾液/血浆比中,夜间比值更接近1.0。

临床怎么用

  • 对于静脉使用利奈唑胺的患者,可考虑采用唾液样本进行浓度监测以减少采血负担。
  • 临床解读唾液浓度时需注意给药途径和采样时间对唾液/血浆比的影响。

局限性

  • 样本量较小(18例),结论需更大规模研究验证。
  • 研究未明确唾液监测的临床阈值或剂量调整标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Linezolid is primarily used to treat of methicillin-resistant Staphylococcus aureus and multidrug-resistant tuberculosis infections. Thrombocytopenia due to linezolid usage is a concern, and therapeutic drug monitoring has been reported to be effective in its prevention. Plasma concentrations provide valuable information for treatment decisions; however, collecting plasma samples can be burdensome for both patients and healthcare providers. Therefore, there is interest in saliva as an alternative for monitoring, considering its potential to replace plasma samples. METHODS: Patients hospitalized at Hokkaido University Hospital and Hokkaido Spinal Cord Injury Center between April 2022 and July 2024, who received oral or intravenous linezolid treatment, were enrolled. The concentrations of linezolid were simultaneously measured in plasma and saliva samples. We determined the concentration profiles of linezolid in the saliva and examined the correlation between saliva and plasma linezolid concentrations. RESULTS: Eighteen patients receiving linezolid were enrolled. The average of saliva/plasma (S/P) concentration ratios of linezolid were 1.018. A strong correlation was found between the salivary and plasma concentrations of linezolid (R = .833, P < .001). Notably, in patients receiving intravenous administration of linezolid, the correlation was even more pronounced (R = .885, P < .001). Additionally, when focusing on the S/P ratio of the trough concentrations in the morning and at night, the S/P ratios at night were much closer to 1.0. CONCLUSION: The concentrations of linezolid in plasma and saliva were similar, indicating their potential applicability in clinical settings. The monitoring of linezolid concentrations in saliva has been shown to be particularly suitable for patients receiving intravenous administration.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Inoue Y, Kashiwagi H, Sato Y, et al. Clinical research for saliva-based therapeutic drug monitoring of linezolid. Br J Clin Pharmacol. 2024. PMID: 39389066. doi:10.1111/bcp.16278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。